Omnicell (NASDAQ:OMCL) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Omnicell (NASDAQ:OMCL) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks reports.

Several other analysts have also recently commented on OMCL. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Wells Fargo & Company reduced their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $33.88 on Monday. The stock has a market capitalization of $1.54 billion, a P/E ratio of 40.33, a price-to-earnings-growth ratio of 0.86 and a beta of 0.97. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell has a 1 year low of $29.06 and a 1 year high of $55.00. The firm has a 50 day moving average of $39.06 and a 200-day moving average of $39.21.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same period in the prior year, the company earned $0.45 EPS. Omnicell’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, sell-side analysts anticipate that Omnicell will post 1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in OMCL. Nykredit A S bought a new position in Omnicell in the second quarter valued at about $26,000. Raymond James Financial Inc. bought a new stake in Omnicell during the 2nd quarter worth about $26,000. Versant Capital Management Inc raised its holdings in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the last quarter. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in Omnicell during the 4th quarter valued at about $58,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.